Leeaf conducts prospective observational research study to investigate factors influencing the outcome of controlled ovarian stimulation.
To contribute to the improvement of fertility treatment outcomes on a larger scale, Leeaf has dedicated much of 2022 to the design of a comprehensive prospective scientific study to verify the effectiveness of data and AI-driven treatment personalization in increasing pregnancy and take-home baby rates for infertile couples. This prospective study investigates the effect of four-dimensional patient data (medical, lifestyle, environmental, and genetic) on the outcomes of ovarian stimulation for IVF.
As Leeaf advocates for data to enable physicians to make better decisions in fertility treatment selection, this study creates a meaningful combination of medical knowledge, unique physician experience and information derived from data analysis. Leeaf has successfully built the necessary technological infrastructure and assembled an international scientific board consisting of high-profile IVF experts across the Czech Republic, Hungary, Spain, the United Kingdom, and the United States.
“The grand vision for 2023 is to successfully complete the first prospective research study with high quality data and to prove the efficacy of our algorithms and models through randomized control trials (RCT) based on the data collected,” adds Jan Choma, Co-Founder and Co-CEO of Leeaf, who oversees research activities and coordinates the medical and scientific boards.
Building on several previously completed scientific studies on artificial intelligence in IVF, Leeaf is conducting this prospective, multi-centric, international study with richer than ever four-dimensional patient data to allow scientists to look deeper into factors that may influence the outcomes of controlled ovarian stimulation. The study is carried out utilising standardised lab work, centralised coordination, and pre-defined patient selection criteria. First clinics have joined the study at the end of 2022 with more clinics expected to join throughout the year. Preliminary results are expected to be available in the second half of 2023.
